The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms: A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled Crossover Laboratory Classroom Study
Ann C Childress, Matthew Brams, Andrew J Cutler, Scott H Kollins, Jo Northcutt, Americo Padilla, John M Turnbow, Ann C Childress, Matthew Brams, Andrew J Cutler, Scott H Kollins, Jo Northcutt, Americo Padilla, John M Turnbow
Abstract
Objective: The study goal was to determine the efficacy and safety of an optimal dose of Evekeo, racemic amphetamine sulfate, 1:1 d-amphetamine and l-amphetamine (R-AMPH), compared to placebo in treating children with attention-deficit/hyperactivity disorder (ADHD) in a laboratory classroom setting.
Methods: A total of 107 children ages 6-12 years were enrolled in this multicenter, dose-optimized, randomized, double-blind, placebo-controlled crossover study. After 8 weeks of open-label dose optimization, 97 subjects were randomized to 2 weeks of double-blind treatment in the sequence of R-AMPH followed by placebo (n=47) or placebo followed by R-AMPH (n=50). Efficacy measures included the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) Rating Scale and Permanent Product Measure of Performance (PERMP) administered predose and at 0.75, 2, 4, 6, 8, and 10 hours postdose on 2 laboratory classroom days. Safety assessments included physical examination, chemistry, hematology, vital signs, and treatment-emergent adverse events (TEAEs).
Results: Compared to placebo, a single daily dose of R-AMPH significantly improved SKAMP-Combined scores (p<0.0001) at each time point tested throughout the laboratory classroom days, with effect onset 45 minutes postdose and extending through 10 hours. R-AMPH significantly improved PERMP number of problems attempted and correct (p<0.0001) throughout the laboratory classroom days. During the twice-daily dose-optimization open-label phase, improvements were observed with R-AMPH in scores of the ADHD-Rating Scale IV and Clinical Global Impressions Severity and Improvement Scales. TEAEs and changes in vital signs associated with R-AMPH were generally mild and not unexpected. The most common TEAEs in the open-label phase were decreased appetite (27.6%), upper abdominal pain (14.3%), irritability (14.3%), and headache (13.3%).
Conclusions: Compared to placebo, R-AMPH was effective in treating children aged 6-12 years with ADHD, beginning at 45 minutes and continuing through 10 hours postdose, and was well tolerated.
Trial registration: ClinicalTrials.gov identifier: NCT01986062. https://ichgcp.net/clinical-trials-registry/NCT01986062.
Figures
References
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed., Text Revision (DSM-IV-TR). Washington, DC: American Psychiatric Association; 2000
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. (DSM-5). Arlington, VA: American Psychiatric Association; 2013
- Arnold LE, Wender PH, McCloskey K, Snyder SH: Levoamphetamine and dextroamphetamine: Comparative efficacy in the hyperkinetic syndrome. Assessment by target symptoms. Arch Gen Psychiatry 27:816–822, 1972
- Barbaresi WJ, Katusic SK, Colligan RC, Weaver AL, Jacobsen SJ: Modifiers of long-term school outcomes for children with attention-deficit/hyperactivity disorder: Does treatment with stimulant medication make a difference? Results from a population-based study. J Dev Behav Pediatr 28:274–287, 2007
- Biederman J, Lopez FA, Boellner SW, Chandler MC: A randomized, double-blind, placebo-controlled, parallel-group study of SLI381 (Adderall XR) in children with attention-deficit/hyperactivity disorder. Pediatrics 110:258–266, 2002
- Biederman J, Petty CR, Woodworth KY, Lomedico A, Hyder LL, Faraone SV: Adult outcome of attention-deficit/hyperactivity disorder: A controlled 16-year follow-up study. J Clin Psychiatry 73:941–950, 2012
- Busner J, Targum SD. The Clinical Global Impressions Scale: Applying a research tool in clinical practice. Psychiatry 4:28–37, 2007
- DuPaul G, Power T, Anastopoulos A, Reid R: ADHD Rating Scale IV: Checklists, Norms, and Clinical Interpretations. New York:Guildford, 1998
- Easton N, Steward C, Marshall F, Fone K, Marsden C: Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology 52:405–414, 2007
- Ghodse H: Ghodse's Drugs and Addictive Behavior: A Guide to Treatment. Cambridge, United Kingdom: Cambridge University Press; 2010
- Greenhill LL, Swanson JM, Steinhoff K, Fried J, Posner K, Lerner M, Wigal S, Clausen SB, Zhang Y, Tulloch S: A pharmacokinetic/pharmacodynamic study comparing a single morning dose of Adderall to twice-daily dosing in children with ADHD. J Am Acad Child Adolesc Psychiatry 42:1234–1241, 2003
- Heal DJ, Smith SL, Gosden J, Nutt DJ: Amphetamine, past and present—a pharmacological and clinical perspective. J Psychopharmacol 27:479–496, 2013
- Heal DJ, Smith SL, Kulkarni RS, Rowley HL: New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD. Pharmacol Biochem Behav 90:184–197, 2008
- Hodgkins P, Shaw M, McCarthy S, Sallee FR: The pharmacology and clinical outcomes of amphetamines to treat ADHD: Does composition matter? CNS Drugs 26:245–268, 2012
- Pliszka S: Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 46:894–921, 2007
- Robb AS, Findling RL, Childress AC, Berry SA, Belden HW, Wigal SB: Efficacy, safety, and tolerability of a novel methylphenidate extended-release oral suspension (MEROS) in ADHD. J Atten Disord 2014. doi: 10.1177/10870547/4533191 [Epub ahead of print]
- Sagvolden T, Xu T: l-Amphetamine improves poor sustained attention while d-amphetamine reduces overactivity and impulsiveness as well as improves sustained attention in an animal model of Attention-Deficit/Hyperactivity Disorder (ADHD).Behav Brain Funct 4:3, 2008
- Swanson JM, Wigal S, Greenhill LL, Browne R, Waslik B, Lerner M, Williams L, Flynn D, Agler D, Crowley K, Fineberg E, Baren M, Cantwell DP: Analog classroom assessment of Adderall in children with ADHD. J Am Acad Child Adolesc Psychiatry 37:519–526, 1998
- Visser SN, Danielson ML, Bitsko RH, Holbrook JR, Kogan MD, Ghandour RM, Perou R, Blumberg SJ: Trends in the parent-report of health care provider-diagnosed and medicated attention-deficit/hyperactivity disorder: United States, 2003–2011. J Am Acad Child Adolesc Psychiatry 53:34–46.e32, 2014
- Wigal SB, Wigal TL: The laboratory school protocol: Its origin, use, and new applications. J Atten Disord 10:92–111, 2006
- Willcutt EG: The prevalence of DSM-IV attention-deficit/hyperactivity disorder: A meta-analytic review. Neurotherapeutics 9:490–499, 2012
- Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S: ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128:1007–1022, 2011a
- Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S: Process of care supplemental appendix. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128:SI1–SI21, 2011b
Source: PubMed